BEXSERO
Multicomponent Meningococcal B Vaccine
(recombinant, adsorbed)

Multicomponent Meningococcal B Vaccine
(recombinant, adsorbed)
BEXSERO was developed, using a multiple antigen approach. Immunization with BEXSERO is intended to raise the titer of bactericidal antibodies that specifically bind the vaccine antigens fHbp, NadA, NHBA and PorA P1.4 (the immunodominant antigen present in the OMV component). 1*
fHbp
Factor H binding protein
NadA
Neisserial adhesin A
NHBA
Neisseria Heparin Binding Antigen
OMV
Outer Membrane Vesicles that contain PorA 1.4
* Clinical significance unknown.
This page is for Healthcare Professionals only. If you are not a Healthcare Professional, please visit Bexsero.ca.